Standout Papers
- An analysis of the attrition of drug candidates from four major pharmaceutical companies (2015)
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival (2011)
- Phase II and Phase III attrition rates 2011–2012 (2013)
- Phase II failures: 2008–2010 (2011)
- Phase III and submission failures: 2007–2010 (2011)
Immediate Impact
5 by Nobel laureates 26 from Science/Nature 60 standout
Citing Papers
admetSAR3.0: a comprehensive platform for exploration, prediction and optimization of chemical ADMET properties
2024 Standout
Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction
2024 Standout
Works of John Arrowsmith being referenced
An analysis of the attrition of drug candidates from four major pharmaceutical companies
2015 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| John Arrowsmith | 343 | 1291 | 276 | 800 | 384 | 18 | 3.2k | |
| Christopher T. Dunwiddie | 229 | 1163 | 385 | 808 | 191 | 37 | 3.3k | |
| Bernard Munos | 195 | 1178 | 67 | 1003 | 178 | 12 | 3.4k | |
| Stacy Lindborg | 148 | 998 | 63 | 792 | 170 | 25 | 4.0k | |
| Sudeep Pushpakom | 210 | 1519 | 97 | 837 | 417 | 24 | 3.5k | |
| Daniel S. Mytelka | 146 | 991 | 48 | 782 | 250 | 17 | 2.5k | |
| Katherine J. Escott | 227 | 1588 | 97 | 848 | 354 | 18 | 3.3k | |
| David Cavalla | 250 | 1582 | 83 | 876 | 322 | 29 | 3.2k | |
| Tim Guilliams | 232 | 1898 | 80 | 870 | 314 | 15 | 3.8k | |
| Philippe Sanséau | 241 | 2883 | 124 | 1259 | 470 | 46 | 5.3k | |
| Christine J. McNamee | 210 | 1534 | 78 | 831 | 313 | 14 | 3.0k |
All Works
Loading papers...